Signs of Carcinoid Heart Disease on Staging CT: Which Predictors are Helpful? Abstract #1077

Introduction: In patients with functionally active neueroendocrine neoplasms (NEN) carcinoid heart disease presenting primarily with tricuspid valve regurgitation (TR) is associated with high morbidity and mortality. Early diagnosis is crucial to improve prognosis.
Aim(s): To evaluate signs on CT imaging performed for tumor staging as predictors of TR in patients with functionally active NEN.
Materials and methods: Patients with functionally active NEN and different grades of TR were identified. Two readers independently reviewed contrast-enhanced staging CT performed shortly before or after echocardiography. Logistic regression and receiver operating analyses were used to asses the predictive value of right ventricle to left ventricle ratio (RV/LV ratio), ventricular septal bowing, retrograde contrast filling of the hepatic veins during contrast injection, and time to aortal enhancement >100 HU during bolus tracking (TAE >100 HU) for TR.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. med. Alexander Baur

To read results and conclusion, please login ...

Further abstracts you may be interested in

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong
#230 Long-term Follow-up of Tissue Valve Prostheses in Carcinoid Heart Disease
Introduction: Development of carcinoid heart disease (CHD) increases morbidity and mortality. Cardiac valve replacement surgery improves functional class, but tissue prosthesis degeneration can occur early in CHD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel S Knight
#261 Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks
Authors: Zacks J, Shafir M, Castillo J, Choi J, ...
#356 Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Introduction: Carcinoid heart disease (CHD), a complication of NETs, is characterized by right heart fibrotic lesions. In addition to serotonin, cytokines and growth factors with fibrogenic properties may play a role.
Conference:
Category: Basic
Presenting Author: MD, PhD Deidi S. Bergestuen